Elon Musk: ‘mRNA Surest Path to Curing Cancer’

In an interview, Twitter CEO Elon Musk blistered BBC ‘journalist’ James Clayton about the outlet’s double standards regarding COVID-19 misinformation.

Musk rightfully called out Clayton’s nonsensical claims that ‘hate speech’ has risen since Musk took over as Twitter CEO.

Clayton couldn’t name one example to support his claims.

While backed into a corner, Clayton moved the conversation to COVID-19 misinformation.

Clayton asked Musk why Twitter changed its policies related to COVID-19.

Musk flipped the conversation and asked if the BBC changed its COVID-19 misinformation.

“You changed the labels. The COVID misinformation labels. There used to be a policy then that disappeared,” Clayton said.

“Why do that?” he asked.

“COVID is no longer an issue,” Musk replied.

Musk flipped the conversation back to Clayton and the BBC.

“Does the BBC hold itself at all responsible for misinformation regarding masking and side effects of vaccinations and not reporting on that at all?” Musk asked.

“And what about the fact that the BBC was put under pressure by the British government to change editorial policy? Are you aware of that?” Musk added.

WATCH:

This time with video & better audio https://t.co/js4nTQSSh3

— Elon Musk (@elonmusk) April 12, 2023

“i think the only good thing about covid was how many eyes were opened to how easy they can be controlled and narratives can be controlled via fear more eyes are open now, which is a good thing, but it was a very painful experience,” Twitter user Shibetoshi Nakamoto replied to the video.

i think the only good thing about covid was how many eyes were opened to how easy they can be controlled and narratives can be controlled via fear

more eyes are open now, which is a good thing, but it was a very painful experience

— Shibetoshi Nakamoto (@BillyM2k) April 12, 2023

In that thread, Musk made a clarification on his opinions about mRNA technology.

Musk said that “accelerating synthetic mRNA technology was another silver lining.”

“I am convinced that synthetic mRNA is the surest path to curing cancer,” he added.

Read the full tweet below:

“This will make some people upset, but I need to emphasize that accelerating synthetic mRNA technology was another silver lining. It is a revolution in medicine, like going from analog to digital. The Covid mRNA vaccine dosage level was too high and having a zillion booster shots was idiotic, causing more harm than good imo, but I am convinced that synthetic mRNA is the surest path to curing cancer, among other things.”

This will make some people upset, but I need to emphasize that accelerating synthetic mRNA technology was another silver lining. It is a revolution in medicine, like going from analog to digital.

The Covid mRNA vaccine dosage level was too high and having a zillion booster shots…

— Elon Musk (@elonmusk) April 12, 2023

Twitter users had comments about Musk’s statement regarding mRNA technology.

I would like to see actual evidence for an mRNA application being beneficial to human beings for anything whatsoever.

https://t.co/xxcZWTlEAa

— Jordan Schachtel @ dossier.today (@JordanSchachtel) April 12, 2023

Elon Musk believes the development of mRNA vaccines has been a positive “silver lining” of the response to COVID. Do you agree with this? https://t.co/SID4lvygee

— Michael P Senger (@michaelpsenger) April 12, 2023

They wanted to test the mRNA technology and the 'pandemic' gave them the perfect opportunity…… https://t.co/hjbgmhvuiv

— Marie Ryan (@AustereInfidel) April 12, 2023

https://twitter.com/Sterling_AF/status/1646249203826589697

So basically the biggest human experiment ever. https://t.co/flbsO77h2m

— Concerned Citizen (@BGatesIsaPyscho) April 12, 2023

In 2020, Tesla teamed up with CureVac to develop ‘RNA microfactories’ for a COVID-19 shot.

From Fierce Pharma:

German vaccine maker CureVac has lost some shine in the race for a COVID-19 shot after other mRNA-based hopefuls have captured regulators’ attention. Even so, CureVac has reportedly snared a big partner to help build its game-changing RNA “printers” that could turn global interest back in its favor.

Tesla CEO Elon Musk tweeted Thursday that the electric carmaker had signed on with CureVac to make portable molecular RNA printers—what Musk appeared to refer to as “RNA microfactories”—to help produce doses of the German vaccine maker’s COVID-19 shot candidate.

Musk said his company was working on the printers as a “side project” and could take on additional partners in the future.

Tesla, as a side project, is building RNA microfactories for CureVac & possibly others

— Elon Musk (@elonmusk) July 2, 2020

Ultimately, CureVac’s COVID-19 shot flopped.

FOX News reported:

Preliminary data behind German biopharmaceutical company CureVac’s COVID 19 mRNA vaccine candidate revealed a disappointing 47% efficacy against COVID-19 disease of any severity, and failed to meet statistical success criteria in a late-stage trial, sending stocks tanking.

“In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria,” the company wrote in a statement posted Wednesday.

The low efficacy comes in contrast to Pfizer and Moderna’s mRNA COVID-19 vaccines with over 90% efficacy and only somewhat diminished protection in the face of viral variants.

Despite the disappointing trials, CureVac still attempted to gain some of the profits from the toxic COVID-19 shots.

CureVac sued BioNTech for patent infringement for technology the company said it developed.

Fierce Pharma noted:

A year after a high-profile flop with its COVID-19 vaccine candidate, CureVac is still trying to get a piece of the action.

On Monday, the company revealed that it is suing fellow German mRNA pioneer BioNTech for infringement of its intellectual property by developing the Pfizer-partnered COVID shot Comirnaty.

CureVac said it has no intention of disrupting the production, sale or distribution of BioNTech’s megablockbuster vaccine with an injunction. Instead, the Tubingen-based company wants recognition and compensation for the technology it developed—beginning with work more than two decades ago—which it says was essential in BioNTech’s creation of its successful shot.

“There’s a piece of IP which we think has been used. That’s OK. We’re not against using it, especially in a pandemic,” CureVac CEO Franz-Werner Haas said in an interview. “We just want to have this piece of contribution to be recognized.”

Share your thoughts in the comments.